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1. INTRODUCTION {#cas14455-sec-0001}
===============

The tumor microenvironment (TME) is comprised of tumor cells surrounded by other components including tumor vessels, CAFs, inflammatory cells, and the extracellular matrix (ECM).[^1^](#cas14455-bib-0001){ref-type="ref"} Interactions between TME components and malignant cancer cells, either through direct cell‐cell contact or secretion of various cytokines, can regulate the characteristics of tumor tissues and affect spatiotemporal tumor progression and metastasis. Thus, a better understanding of the interaction between cancer cells and the TME is important for the development of novel therapeutic targets.

TME undergoes dynamic changes during tumorigenesis. For example, stromal cells differentiate into CAFs. However, recent lines of evidence have revealed that a subset of CAFs arises from ECs lining the tumor vessels, in a process called EndMT.[^2^](#cas14455-bib-0002){ref-type="ref"}, [^3^](#cas14455-bib-0003){ref-type="ref"}, [^4^](#cas14455-bib-0004){ref-type="ref"} During EndMT, ECs change their characteristics and acquire a mesenchymal phenotype. They also lose their cell‐cell contacts, decrease expression of endothelial cell‐specific markers, eg vascular endothelial‐cadherin (VE‐cadherin), and increase expression of various mesenchymal cell markers, including smooth muscle protein 22α (SM22α).[^2^](#cas14455-bib-0002){ref-type="ref"} We recently reported that transforming growth factor‐β (TGF‐β) induced the transition from tumor ECs (TECs) to α‐smooth muscle actin (αSMA)‐positive mesenchymal cells (myofibroblasts), which induced tumor formation more potently than αSMA‐negative TEC‐derived mesenchymal cells.[^5^](#cas14455-bib-0005){ref-type="ref"} In addition to formation of CAFs during EndMT, loss of the endothelial barrier of the tumor vasculature can be observed, suggesting an important role of EndMT in facilitating metastatic dissemination. Thus, effective targeting of EndMT is likely to result in the development of novel anti‐cancer therapies.[^6^](#cas14455-bib-0006){ref-type="ref"}

There are various cytokines present within the TME, among which TGF‐βs have been well studied. TGF‐βs are mostly secreted by cancer cells and infiltrating inflammatory cells residing in the TME. As revealed by previous studies, TGF‐β within the TME can induce the EMT of normal and transformed epithelial cells[^7^](#cas14455-bib-0007){ref-type="ref"} as well as EndMT of ECs.[^2^](#cas14455-bib-0002){ref-type="ref"} In mammals, TGF‐β, belonging to the TGF‐β family, is comprised of 33 members, including TGF‐βs, bone morphogenetic proteins (BMPs), activins, Nodal, and others.[^7^](#cas14455-bib-0007){ref-type="ref"} All members of the TGF‐β family transduce their signals through 2 types of transmembrane receptors.[^8^](#cas14455-bib-0008){ref-type="ref"} Ligand binding of activin, TGF‐β, and Nodal to a constitutively active type II receptor kinase results in phosphorylation of the type I receptors, activin receptor‐like kinases (ALK)‐4, ALK‐5, and ALK‐7, respectively, which in turn activate downstream signal transduction cascades, including receptor‐regulated Smad (R‐Smad) pathways. Activated R‐Smads can then form a complex with the common mediator Smad4 (co‐Smad), stimulating nuclear translocation to interact with various transcription factors and regulating transcription of target genes. Various R‐Smads participate in signaling cascades depending on the activating ligand, eg Smad2 and 3 transduce signals for TGF‐βs and activins, while Smad1, 5, and 8 are responsible for BMP‐dependent signaling.

There are 3 isotypes of TGF‐β: TGF‐β1, TGF‐β2, and TGF‐β3. They exhibit different activities and are differentially expressed in multiple cancer types. For example, glioma cells preferentially express the TGF‐β2 isoform.[^9^](#cas14455-bib-0009){ref-type="ref"}, [^10^](#cas14455-bib-0010){ref-type="ref"} Of interest, our previous reports showed that TGF‐β2 could induce EndMT of various types of ECs.[^5^](#cas14455-bib-0005){ref-type="ref"}, [^11^](#cas14455-bib-0011){ref-type="ref"}, [^12^](#cas14455-bib-0012){ref-type="ref"}, [^13^](#cas14455-bib-0013){ref-type="ref"}, [^14^](#cas14455-bib-0014){ref-type="ref"} However, it remains to be elucidated how TGF‐β2 expression is regulated in ECs.

TGF‐β proteins are initially synthesized in the endoplasmic reticulum as precursor proteins containing growth factor and latency‐associated peptide (LAP) and remain covalently linked, even after Golgi processing. Formation of this complex retains TGF‐β in its inactive form. Moreover, this TGF‐β complex is considered as a sensor when secreted into the ECM, since active TGF‐β is only released from LAP during activation.[^15^](#cas14455-bib-0015){ref-type="ref"} There are several mechanisms responsible for TGF‐β activation. For example, integrins, especially integrin αvβ6 and integrin αvβ8, have been shown to play important roles in releasing active TGF‐β through binding of RGD sequence of LAP to integrins.[^16^](#cas14455-bib-0016){ref-type="ref"}, [^17^](#cas14455-bib-0017){ref-type="ref"}, [^18^](#cas14455-bib-0018){ref-type="ref"}, [^19^](#cas14455-bib-0019){ref-type="ref"} In addition, other types of αv integrins, such as αvβ1, αvβ3, and αvβ5, have been suggested to interact with LAP and activate latent TGF‐β.[^20^](#cas14455-bib-0020){ref-type="ref"}, [^21^](#cas14455-bib-0021){ref-type="ref"}, [^22^](#cas14455-bib-0022){ref-type="ref"} RGD sequences are present in the LAPs of TGF‐β1 and TGF‐β3, but not in the LAP of TGF‐β2; thus the mechanisms of activation of latent TGF‐β2 remain to be elucidated.

The TGF‐β‐induced mesenchymal transition of endothelial and epithelial cells can be regulated by various factors. For example, our recent report showed endogenous fibroblast growth factor 2 (FGF2) to modulate TGF‐β‐dependent mesenchymal transition of mouse TECs.[^5^](#cas14455-bib-0005){ref-type="ref"} Other reports have suggested an important role of inflammation in tumor progression. Inflammatory cells residing within the TME produce inflammatory cytokines to affect the EMT of cancer cells. Indeed, previous reports have shown that activated macrophages produce various proinflammatory cytokines, including tumor necrosis factor‐α (TNF‐α).[^23^](#cas14455-bib-0023){ref-type="ref"} In addition, we have reported that TGF‐β‐induced EMT of A549 lung cancer cells can be augmented in the presence of TNF‐α.[^24^](#cas14455-bib-0024){ref-type="ref"} Specifically, A549 cells treated with both cytokines exhibited more profound loss of cell adhesive properties, while gaining migratory and invasive abilities characteristic of mesenchymal cells. TNF‐α can also directly affect ECs. Brett and colleagues have shown that TNF‐α increased vascular leakage and permeability of endothelial monolayer.[^25^](#cas14455-bib-0025){ref-type="ref"} Moreover, TNF‐α activates both inhibitor of κB kinase/nuclear factor‐κB (NF‐κB) and mitogen‐activated protein kinase/AP‐1 pathways, which are essential for the expression of proinflammatory cytokines and the induction of many biological events occurring downstream of TNF‐α, including decreased barrier function of the endothelium.[^26^](#cas14455-bib-0026){ref-type="ref"}

TNF‐α and another proinflammatory cytokine, interleukin‐1β (IL‐1β), have been reported to induce EndMT of various types of ECs.[^27^](#cas14455-bib-0027){ref-type="ref"}, [^28^](#cas14455-bib-0028){ref-type="ref"}, [^29^](#cas14455-bib-0029){ref-type="ref"} However, the mechanisms underlying the role of TNF‐α in enhancing TGF‐β‐induced EndMT are poorly understood. In this study, we examined the effect of TNF‐α on TGF‐β‐induced EndMT using multiple types of human ECs. We observed a TGF‐β‐dependent increase in the expression of various mesenchymal cell markers, including SM22α. In addition, ECs treated with a combination of TGF‐β and TNF‐α showed higher expression of TGF‐β type I receptor (ALK5), TGF‐β2, activin A, and integrin αv compared with cells cultured in the presence of either cytokine, suggesting cooperation between TGF‐β and TNF‐α in augmenting TGF‐β signals and enhancing EndMT. In addition, ECs that gained mesenchymal characteristics seemed to participate in the formation of a TGF‐β2‐rich microenvironment, which induced the EMT of oral cancer cells, suggesting a direct link between EndMT and EMT in TME.

2. MATERIALS AND METHODS {#cas14455-sec-0002}
========================

2.1. Cell culture and reagents {#cas14455-sec-0003}
------------------------------

Human umbilical artery endothelial cell (HUVEC) were purchased from Cell Systems and maintained in the EBM ^TM^‐2MV Bullet Kit (cc‐3202; Lonza). HUVECs were purchased from Lonza and maintained in the EBM ^TM^ Bullet Kit (cc‐3156; Lonza). HEK‐Blue^TM^ TGF‐β cells (HEK293 cell‐derived TGF‐β responsive reporter cells) were purchased from InvivoGen and maintained in dulbecco\'s modified eagle\'s medium (DMEM) (Nacalai Tesque) supplemented with 10% fetal bovine serum (FBS; Sigma), 100 units/mL penicillin, and 100 μg/mL streptomycin (Nacalai Tesque). HSC‐4 cells were obtained from RIKEN Bioresource Center Cell Bank and maintained in DMEM supplemented with 10% FBS. TGF‐β2 and TNF‐α were purchased from Peprotech. IL‐1β was purchased from FUJIFILM Wako Pure Chemical. Follistatin, anti‐pan TGF‐β neutralizing antibody (1D11) and control IgG were purchased from R&D Systems.

2.2. RNA interference {#cas14455-sec-0004}
---------------------

The siRNAs for human RELA (silencer select siRNA ID \#A: s11915, \#B: s224527) and silencer negative control (Cat. AM4611) were purchased from Invitrogen (Carlsbad). All siRNAs were introduced into the HUAECs using Lipofectamine RNAi Max reagent (Invitrogen) according to the manufacturer\'s instructions. Briefly, 2.8 × 10^4^ cells were mixed with siRNA‐Lipofectamine complexes and seeded into 6‐well plates. Medium was refreshed 6 h later and cells were allowed to grow for an indicated period.

2.3. RNA isolation and quantitative RT‐PCR {#cas14455-sec-0005}
------------------------------------------

Total RNA was prepared using the NucleoSpin RNA (TaKaRa Bio), according to the manufacturer\'s protocol, and reverse‐transcribed by random priming using a PrimeScript II Kit (TaKaRa Bio). Quantitative RT‐PCR (qRT‐PCR) analysis was performed using the StepOne Plus Real‐Time PCR System (Thermo Fisher Scientific). All expression data were normalized to β‐actin expression. The primer sequences used in the present study are available in Table [S1](#cas14455-sup-0001){ref-type="supplementary-material"}.

2.4. Smad2/3‐responsive reporter assay {#cas14455-sec-0006}
--------------------------------------

Activation of Smad2/3 signals by TGF‐β family members, including TGF‐β1, TGF‐β2, TGF‐β3 and activin, was determined using a reporter assay that employed HEK‐Blue^TM^ TGF‐β cells, allowing quantification of soluble alkaline phosphatase (SEAP) activity expressed under the control of Smad2/3/4‐inducible elements. HUAECs were treated with TGF‐β2 and TNF‐α for 60 h. The culture medium was then replaced with DMEM with 1% FBS, followed by incubation for additional 16 h. The CM was then collected and added to the pre‐seeded HEK‐Blue^TM^ TGF‐β reporter cells, followed by incubation for 24 h. Fraction of the medium obtained from incubation with HEK‐Blue cells was then mixed with QUANTI‐Blue substrate (InvivoGen) and incubated for 30 min. The colorimetric change of the substrate by the released SEAP was quantified at 640 nm using a spectrophotometer.

2.5. Immunocytochemistry {#cas14455-sec-0007}
------------------------

HUAECs were seeded on cover glasses pre‐coated with Cellmatrix Type I‐C (Nitta Gelatin) and cultured in the presence or absence of TGF‐β2 and/or TNF‐α for 72 h. The cells were then fixed with 4% paraformaldehyde, treated with 0.1% Triton X‐100, blocked, and incubated with primary anti‐SM22α (ab14106, abcam), followed by treatment with Alexa 594‐conjugated secondary antibodies and Hoechst33342 for nuclear staining. Images were obtained using an All‐in‐One fluorescence microscope, BZ‐X710 (KEYENCE).

HSC‐4 cells were seeded on cover glasses and cultured with serum‐free medium for 3 h. Then, the medium was changed to the CM of HUAECs cultured in the presence or absence of TGF‐β2 and/or TNF‐α for 72 h. Cells were then fixed with an ice‐cold mixture of methanol‐acetone (1:1) for 20 s, blocked with 1% BSA, and incubated with anti‐epithelial‐cadherin (E‐cadherin) (1:200 dilution, 3195; Cell Signaling Technology) and anti‐Vimentin (1:400 dilution, ab92547; abcam) antibodies, followed by treatment with anti‐mouse IgG (H+L) Alexa 488‐conjugated (A‐11001; Thermo Fisher Scientific) and anti‐rabbit IgG (H + L) Alexa 594‐conjugated (A‐21207; Thermo Fisher Scientific) secondary antibodies and Hoechst33342 for nuclear staining. Images were obtained using a confocal microscope, TCS SP8 (Leica Microsystems GmbH).

2.6. Tube formation assay {#cas14455-sec-0008}
-------------------------

A 12‐well plate was pre‐coated with Matrigel (BD Biosciences) (0.4 mL/well). After polymerization of Matrigel at 37°C for 1 h, HUAECs were seeded to each well at a density of 1.7 × 10^5^ cells/400 µL/well. After 8 h of incubation in EGM‐2MV medium supplemented with 5% FBS, tube‐like structures were photographed under phase‐contrast microscopy (BZ‐X710, KEYENCE) using a ×10 objective lens. Tube length was quantified using ImageJ software (US National Institutes of Health).

2.7. Statistical analyses {#cas14455-sec-0009}
-------------------------

Values are presented as mean ± standard deviation or standard error. Significant differences between means were determined using two‐tailed unpaired Student *t* test or one‐way ANOVA followed by the Student‐Newman‐Keuls test. Differences between means were considered statistically significant at \**P* \< .05; n.s., not significant.

3. RESULTS {#cas14455-sec-0010}
==========

3.1. TNF‐α augments TGF‐β signals in human ECs {#cas14455-sec-0011}
----------------------------------------------

To examine whether TGF‐β and TNF‐α could transduce signals in HUAECs, we analyzed the effect of both cytokines on the expression level of target genes related to each pathway. Treatment of HUAECs with TGF‐β2 for 4 h significantly induced the expression of transmembrane prostate androgen‐induced protein (TMEPAI), a faithful target of Smad2/3 signals (Figure [1A](#cas14455-fig-0001){ref-type="fig"}), while TNF‐α alone slightly suppressed TMEPAI expression, which was further suppressed by combined treatment of TGF‐β2 and TNF‐α. In contrast, the expression of ICAM1, a direct target gene of TNF‐α signals, was significantly increased by treatment with TNF‐α but not by TGF‐β2 (Figure [1B](#cas14455-fig-0001){ref-type="fig"}). TGF‐β2 had no effect on the TNF‐α‐induced ICAM1 expression at 4 h.

![Effects of TGF‐β2 and TNF‐α on the expression of TGF‐β2 and TNF‐α target genes in HUAECs. HUAECs were cultured in the absence (−) or presence (+) of 1 ng/mL TGF‐β2 in combination with 10 ng/mL TNF‐α for 4 h (A, B) or 72 h (C, D), followed by qRT‐PCR analyses for *TMEPAI* (A, C) and *ICAM1* (B, D) expression. Error bars represent standard deviation. \**P* \< 0.05](CAS-111-2385-g001){#cas14455-fig-0001}

Subsequently, we examined whether the expression of TMEPAI and ICAM1 is maintained in HUAECs that are treated with TGF‐β and TNF‐α for longer period. Increased expression of TMEPAI was observed in HUAECs treated with TGF‐β2 for 72 h (Figure [1C](#cas14455-fig-0001){ref-type="fig"}). Furthermore, these changes were also observed with TNF‐α alone (Figure [1C](#cas14455-fig-0001){ref-type="fig"}) to a lesser extent. Interestingly, a combination of TGF‐β2 and TNF‐α for 72 h induced an even higher level of TMEPAI expression (approximately 3‐fold) than TGF‐β2 alone (Figure [1C](#cas14455-fig-0001){ref-type="fig"}). Furthermore, following a 72‐h incubation with TNF‐α, HUAECs increased ICAM1 expression (Figure [1D](#cas14455-fig-0001){ref-type="fig"}). However, combined treatment with TGF‐β2 and TNF‐α for 72 h suppressed ICAM1 expression, compared with TNF‐α alone (Figure [1D](#cas14455-fig-0001){ref-type="fig"}). These results suggested that both TGF‐β and TNF‐α could transduce their signals in HUAECs and that HUAECs treated with both cytokines may acquire the characteristics needed to more potently transduce certain TGF‐β signals.

3.2. TNF‐α enhances TGF‐β‐induced expression of mesenchymal cell markers in various types of ECs {#cas14455-sec-0012}
------------------------------------------------------------------------------------------------

We have previously reported that TGF‐β2 could induce EndMT in multiple types of mouse ECs, including embryonic stem cell‐derived ECs,[^12^](#cas14455-bib-0012){ref-type="ref"} MS1 ECs,[^13^](#cas14455-bib-0013){ref-type="ref"} and TECs.[^5^](#cas14455-bib-0005){ref-type="ref"} Therefore, to examine whether TGF‐β2 would elicit the same effect in human ECs, we analyzed the expression of various mesenchymal and EC markers in HUAECs treated with TGF‐β2 for 72 h (Figure [2](#cas14455-fig-0002){ref-type="fig"}). We observed increased expression of mesenchymal cell markers, SM22α (Figure [2A](#cas14455-fig-0002){ref-type="fig"}) and matrix metalloproteinase 2 (MMP2) (Figure [2B](#cas14455-fig-0002){ref-type="fig"}), which was accompanied by decreased expression of Claudin 5 (CLDN5), an EC marker (Figure [2C](#cas14455-fig-0002){ref-type="fig"}), suggesting that HUAECs underwent EndMT. Further, we examined the effect of TNF‐α on the TGF‐β‐induced EndMT (Figure [2](#cas14455-fig-0002){ref-type="fig"}). While treatment of HUAECs with TNF‐α alone did not alter expression of mesenchymal or EC markers, TNF‐α significantly enhanced TGF‐β2‐induced expression of SM22α (Figure [2A](#cas14455-fig-0002){ref-type="fig"}), MMP2 (Figure [2B](#cas14455-fig-0002){ref-type="fig"}) and CLDN5 (Figure [2C](#cas14455-fig-0002){ref-type="fig"}). Similar results were obtained using HUVECs in which TNF‐α significantly enhanced TGF‐β2‐induced expression of SM22α, but did not significantly enhance TGF‐β2‐induced MMP2 expression and TGF‐β2‐suppressed CLDN5 expression (Figure [2D‐F](#cas14455-fig-0002){ref-type="fig"}).

![Effects of TGF‐β2 and TNF‐α on endothelial and mesenchymal characteristics of multiple types of endothelial cells. HUAECs (A‐C) and HUVECs (D‐F) were cultured in the absence (−) or presence (+) of 1 ng/mL TGF‐β2 in combination with 10 ng/mL TNF‐α (HUAECs) and 15 ng/mL TNF‐α (HUVECs), respectively, for 72 h, followed by qRT‐PCR analyses for *SM22α* (A, D), *MMP2* (B, E), and Claudin 5 (*CLDN5*) (C, F) expression. Error bars represent standard deviation. \**P* \<0.05; n.s., not significant](CAS-111-2385-g002){#cas14455-fig-0002}

The effect of TNF‐α on TGF‐β2‐induced expression of SM22α was also confirmed at the protein level (Figures [3](#cas14455-fig-0003){ref-type="fig"} and [S1](#cas14455-sup-0001){ref-type="supplementary-material"}). We observed changes in cell morphology and strong staining with anti‐SM22α antibodies in TGF‐β2‐treated HUAECs (Figures [3A](#cas14455-fig-0003){ref-type="fig"} and [S1](#cas14455-sup-0001){ref-type="supplementary-material"}, upper right panel). In addition, the number of SM22α‐positive cells increased when cells were treated with a combination of TGF‐β2 and TNF‐α (Figure [3B](#cas14455-fig-0003){ref-type="fig"}), suggesting that TNF‐α could enhance TGF‐β‐induced expression of mesenchymal cell markers in various types of ECs.

![Effects of TGF‐β2 and TNF‐α on mesenchymal characteristics of HUAECs. HUAECs were cultured in the absence (−) or presence (+) of 1 ng/mL TGF‐β2 in combination with 10 ng/mL TNF‐α for 72 h, followed by fluorescence immunostaining for SM22α (magenta) and nuclei (blue) (A). Scale bar, 100 μm. (B) Numbers of SM22α‐positive cells were counted in 4 fields. Data are shown as the mean ± standard deviation of 4 independent experiments. \**P* \<0.0001.](CAS-111-2385-g003){#cas14455-fig-0003}

Decreased expression of CLDN5, an EC marker, during EndMT (Figure [2C](#cas14455-fig-0002){ref-type="fig"}) prompted us to examine whether HUAECs lose their endothelial functions upon the treatment with TGF‐β2 and TNF‐α by performing tube formation assay. As shown in Figure [4A](#cas14455-fig-0004){ref-type="fig"}, HUAECs exhibited tube forming ability, which is characteristic of ECs. This tube forming ability was significantly decreased by treatment of HUAECs with TGF‐β2 or TNF‐α alone and completely abolished by the combined treatment with TGF‐β2 and TNF‐α (Figure [4B](#cas14455-fig-0004){ref-type="fig"}). Taking together the results of gene expression and tube formation assays, we concluded that HUAECs lost their endothelial phenotypes by treatment with TGF‐β2 and TNF‐α.

![Effects of TGF‐β2 and TNF‐α on tube forming ability of HUAECs. HUAECs were cultured in the absence (−) or presence (+) of 1 ng/mL TGF‐β2 in combination with 10 ng/mL TNF‐α for 72 h, followed by tube formation assay. Cells were allowed to form tube‐like structures on a collagen gel for 8 h, followed by phase‐contrast imaging (A) and quantification (B) of tube‐like structures. Scale bars, 200 μm. Error bars represent standard deviation. \**P* \<0.05; ND, not detected](CAS-111-2385-g004){#cas14455-fig-0004}

3.3. TNF‐α cooperates with TGF‐β2 to induce ALK5 expression in various types of ECs {#cas14455-sec-0013}
-----------------------------------------------------------------------------------

In this study, we found that TNF‐α cooperates with TGF‐β2 to induce expression of TMEPAI (Figure [1C](#cas14455-fig-0001){ref-type="fig"}) and various mesenchymal cell markers (Figures [2](#cas14455-fig-0002){ref-type="fig"},[3](#cas14455-fig-0003){ref-type="fig"} and [S1](#cas14455-sup-0001){ref-type="supplementary-material"}) in HUAECs and HUVECs. To elucidate the molecular mechanisms underlying the stimulatory effect of TNF‐α on TGF‐β2‐induced EndMT, expression of various components of the Smad2/3 signaling pathway, which regulates EndMT, was examined at 72 h after ligand stimulation. Smad2/3 signals are activated by the TGF‐β/TGF‐β type II receptor (TβRII)/ALK5 axis and activin/activin type II receptor (ActRIIs)/ALK4/7 and Nodal/ActRIIs/ALK7 axes. Among them, we found that the expression of ALK5, a TGF‐β type I receptor, was induced by TNF‐α, and further increased by TNF‐α and TGF‐β2 (Figure [5A](#cas14455-fig-0005){ref-type="fig"}). Similar results were obtained using HUVECs, which showed significant increases in ALK5 expression in the presence of TNF‐α and TGF‐β2 with no effect on other components of the TGF‐β signaling pathway (Figure [S2](#cas14455-sup-0001){ref-type="supplementary-material"}A). These results suggested that TNF‐α enhanced TGF‐β2‐induced EndMT via activation of TGF‐β signals through increased ALK5 expression, resulting in enhanced TMEPAI expression (Figure [1C](#cas14455-fig-0001){ref-type="fig"}).

![Effects of TGF‐β2 and TNF‐α on expression of various TGF‐β signaling components in HUAECs. HUAECs were cultured in the absence (−) or presence (+) of 1 ng/mL TGF‐β2, 10 ng/mL TNF‐α, or a combination of both cytokines for 72 h, followed by qRT‐PCR analyses for expression of *ALK5* (A), TGF‐β1 (*TGFB1*) (B), TGF‐β2 (*TGFB2*) (C), TGF‐β3 (*TGFB3*) (D), inhibin βA (*INHBA*) (E), and integrin αv (*ITGAV*) (F). Error bars represent standard deviation. \**P* \<0.05; n.s., not significant](CAS-111-2385-g005){#cas14455-fig-0005}

3.4. TGF‐β signals increase endogenous expression of TGF‐β2 and activin A, which is enhanced by TNF‐α in various types of ECs {#cas14455-sec-0014}
-----------------------------------------------------------------------------------------------------------------------------

We next analyzed changes in expression of various TGF‐β family ligands upon stimulation with TGF‐β2, TNF‐α, or both cytokines (Figure [5B‐E](#cas14455-fig-0005){ref-type="fig"}). Combined stimulation with TGF‐β2 and TNF‐α failed to increase expression of TGF‐β1 (Figure [5B](#cas14455-fig-0005){ref-type="fig"}), and TGF‐β3 (Figure [5D](#cas14455-fig-0005){ref-type="fig"}) in HUAECs. However, addition of exogenous TGF‐β2 and TNF‐α significantly increased expression of TGF‐β2 (Figure [5C](#cas14455-fig-0005){ref-type="fig"}) and inhibin βA, the subunit of activin A (Figure [5E](#cas14455-fig-0005){ref-type="fig"}), in a similar manner to TMEPAI (Figure [1C](#cas14455-fig-0001){ref-type="fig"}). Furthermore, in HUVECs, very significant increase in TGF‐β2 and inhibin βA transcripts was observed only upon combined treatment with TNF‐α and TGF‐β2 (Figure [S2](#cas14455-sup-0001){ref-type="supplementary-material"}B‐E), suggesting that TGF‐β2‐treated ECs secreted TGF‐β2 and activin A. These changes in endogenous expression of TGF‐β2 and activin A suggest that they stimulate TMEPAI expression to further enhance EndMT.

3.5. TGF‐β and TNF‐α cooperate to increase integrin αv expression in various types of ECs {#cas14455-sec-0015}
-----------------------------------------------------------------------------------------

Various integrins have been implicated in the activation of latent forms of TGF‐β1 and TGF‐β3. Therefore, we examined the putative involvement of integrins in EndMT of HUAECs, induced by the combined treatment of TGF‐β2 and TNF‐α. For this purpose, we studied the effect of TNF‐α and/or TGF‐β2 on the expression of various integrin family members in HUAECs cultured for 72 h in the presence of TGF‐β2, TNF‐α, or a combination of both cytokines. As shown in Figures [5F](#cas14455-fig-0005){ref-type="fig"} and [S2](#cas14455-sup-0001){ref-type="supplementary-material"}F, we found that integrin αv expression increased upon combined treatment with both cytokines in HUAECs and HUVECs, respectively. These results suggested that TGF‐β2 and TNF‐α cooperate to induce integrin αv expression, which may lead to the activation of latent TGF‐β1 and TGF‐β3 proteins.

3.6. NF‐κB‐mediated inflammatory signals enhance TGF‐β‐induced EndMT {#cas14455-sec-0016}
--------------------------------------------------------------------

As TNF‐α transmits its signals via NF‐κB activation in ECs,[^26^](#cas14455-bib-0026){ref-type="ref"} we next examined the role of NF‐κB in enhancement of TGF‐β2‐induced EndMT by TNF‐α. To examine whether the NF‐κB‐mediated pathway is involved in the EndMT, we used siRNAs specific for RelA/p65, an essential signaling component of NF‐κB in the TNF‐α signal. Introduction of RelA siRNAs into HUAECs resulted in more than a 60% decrease in RelA expression (Figure [6A](#cas14455-fig-0006){ref-type="fig"}) and decreased TNF‐α‐induced expression of its target gene, ICAM1 (Figure [6B](#cas14455-fig-0006){ref-type="fig"}). Increased expression of TMEPAI by the combined treatment with TGF‐β2 and TNF‐α for 72 h was also suppressed by RelA knockdown (Figure [6C](#cas14455-fig-0006){ref-type="fig"}), suggesting that activation of TGF‐β signals by TGF‐β2 and TNF‐α required NF‐κB signals in HUAECs. Furthermore, RelA knockdown significantly suppressed the increased expression of SM22α (Figure [6D](#cas14455-fig-0006){ref-type="fig"}), ALK5 (Figure [6E](#cas14455-fig-0006){ref-type="fig"}), TGF‐β2 (Figure [6F](#cas14455-fig-0006){ref-type="fig"}), inhibin βA (Figure [6G](#cas14455-fig-0006){ref-type="fig"}), and integrin αv (Figure [6H](#cas14455-fig-0006){ref-type="fig"}) in the HUAECs treated by the combination of TGF‐β2 and TNF‐α, suggesting that NF‐κB is involved mechanistically in the EndMT induced by TGF‐β2 and TNF‐α. It is of note that the increase in the expression of SM22α and inhibin βA is largely dependent on RelA expression, while other increases in expression of others only partly depended on it.

![Effects of RelA on TGF‐β2 and TNF‐α‐induced expression of various markers in HUAECs. HUAECs transfected with negative control siRNA (NC) or siRNAs for RelA (RelA‐A and RelA‐B) were cultured in the absence (−) or presence (+) of 1 ng/mL TGF‐β2 in combination with 10 ng/mL TNF‐α for 72 h, followed by qRT‐PCR analyses for expression of *RELA* (A), *ICAM1* (B), *TMEPAI* (C), *SM22α* (D), *ALK5* (E), TGF‐β2 (*TGFB2*) (F), inhibin βA (*INHBA*) (G), and integrin αv (*ITGAV*) (H). Error bars represent standard deviation. \**P* \<0.05; n.s., not significant](CAS-111-2385-g006){#cas14455-fig-0006}

NF‐κB mediates signals mediated not only by TNF‐α but also by other inflammatory cytokines including IL‐1β, which is known to be involved in EndMT.[^28^](#cas14455-bib-0028){ref-type="ref"}, [^29^](#cas14455-bib-0029){ref-type="ref"} This situation further prompted us to examine the effects of simultaneous stimulation of HUAECs with TGF‐β2 and IL‐1β. Expression of ICAM1 was induced and sustained by IL‐1β for 72 h (Figure [7A](#cas14455-fig-0007){ref-type="fig"}). IL‐1β‐induced ICAM1 expression was not suppressed by TGF‐β2, indicating that IL‐1β signal is differently regulated by TGF‐β signal from TNF‐α signal. Conversely, TGF‐β2‐induced expression of TMEPAI was increased by IL‐1β in a similar manner as TNF‐α (Figure [7B](#cas14455-fig-0007){ref-type="fig"}). Expression of mesenchymal cell markers, SM22α and MMP2, was also regulated by the combined treatment with TGF‐β2 and IL‐1β in a similar manner as that for TNF‐α (Figure [7C,D](#cas14455-fig-0007){ref-type="fig"}). Taken together, IL‐1β had a similar effect as TNF‐α on TGF‐β‐induced EndMT.

![Effects of TGF‐β2 and IL‐1β on their target genes and mesenchymal cell markers in HUAECs. HUAECs were cultured in the absence (−) or presence (+) of 1 ng/mL TGF‐β2 in combination with 3 ng/mL IL‐1β for 72 h, followed by qRT‐PCR analyses for expression of *ICAM1* (A), *TMEPAI* (B), *SM22α* (C), and *MMP2* (D). Error bars represent standard deviation. \**P* \<0.05; n.s., not significant](CAS-111-2385-g007){#cas14455-fig-0007}

3.7. TGF‐β and TNF‐α cooperate to increase production of humoral factor activating Smad2/3 signal {#cas14455-sec-0017}
-------------------------------------------------------------------------------------------------

We hypothesized that during EndMT induced by TGF‐β2 and TNF‐α, HUAECs produced "humoral factor(s) activating Smad2/3 signal" (Smad2/3 activating factor(s)). To test this hypothesis, a TGF‐β signal‐responsive HEK‐Blue reporter cell system was used to monitor TGF‐β‐induced Smad signaling.[^30^](#cas14455-bib-0030){ref-type="ref"} HUAECs were cultured in the presence of TGF‐β2, TNF‐α, or a combination of both cytokines for 60 h to allow accumulation of the putative Smad2/3 activating factor(s). The HEK‐Blue reporter cells were then grown in HUAEC CM for 24 h, and activity of the "Smad2/3 activating humoral factors" was examined (Figure [8A](#cas14455-fig-0008){ref-type="fig"}). The CM derived from HUAECs cultured in the presence of TGF‐β2 could activate TGF‐β signals in HEK‐Blue reporter cells as compared with the untreated control (Figure [8B](#cas14455-fig-0008){ref-type="fig"}). Interestingly, this effect was enhanced when CM derived from HUAECs treated with TGF‐β2 and TNF‐α was used (Figure [8B](#cas14455-fig-0008){ref-type="fig"}). Our data suggested that the presence of exogenous TGF‐β2 and TNF‐α induced EndMT in HUAECs by activating the Smad pathway and increasing secretion of "Smad2/3 activating humoral factors."

![Quantification of Smad2/3‐activating factors in conditioned medium (CM) of HUAECs using HEK‐Blue TGF‐β reporter cells. (A) HUAECs were cultured in the absence (−) or presence (+) of 1 ng/mL TGF‐β2 in combination with 10 ng/mL TNF‐α for 60 h, followed by DMEM with 1% FBS, replacement and further culture for 16 h. (B) HEK‐Blue TGF‐β cells were cultured in the CM derived from HUAECs cultured for 16 h, followed by the measurement of absorbance at 640 nm, which represented colorimetric change of HEK‐Blue substrate by secreted alkaline phosphatase induced by Smad2/3 signal. (C, D) HEK‐Blue TGF‐β cells were cultured in the CM derived from HUAECs, in the absence (−) or presence (+) of 50 ng/mL of follistatin (C), control IgG (50 μg/mL) and anti‐TGF‐β (1D11: 50 μg/mL) (D), followed by the measurement of the absorbance at 640 nm representing colorimetric change of HEK‐Blue substrate by SEAP alkaline phosphatase induced by Smad2/3 signals. Values were normalized to the number of HUAECs responsible for secretion of Smad2/3‐activating humoral factors. Error bars represent standard deviation. \**P* \<0.05; n.s., not significant](CAS-111-2385-g008){#cas14455-fig-0008}

We further examined the physiological roles of TGF‐β2 (Figure [5C](#cas14455-fig-0005){ref-type="fig"}) and activin A (Figure [5E](#cas14455-fig-0005){ref-type="fig"}) produced by HUAECs in the activation of Smad2/3 signals by using HEK‐Blue reporter cells. When the CM from HUAECs treated with TGF‐β2 and TNF‐α was added to HEK‐Blue cells in combination with follistatin, an inhibitor of activin (Figure [S3](#cas14455-sup-0001){ref-type="supplementary-material"}A), the increased activation of Smad2/3 signals seen upon incubation with the CM was decreased significantly, suggesting that endogenous activin A was responsible for activation of Smad2/3 signals (Figure [8C](#cas14455-fig-0008){ref-type="fig"}). However, anti‐TGF‐β neutralizing antibody (1D11) (Figure [S3](#cas14455-sup-0001){ref-type="supplementary-material"}B) failed to abrogate the activation of Smad2/3 signals by the CM from HUAECs treated with TGF‐β2 and TNF‐α (Figure [8D](#cas14455-fig-0008){ref-type="fig"}). These results suggested that EndMT induced by TGF‐β2 and TNF‐α increased the production of endogenous activin A from HUAECs, which led to the sustained activation of Smad2/3 signals.

3.8. Oral squamous cell carcinoma‐derived cells undergo EMT in response to humoral factors produced by TGF‐β and TNF‐α‐treated ECs {#cas14455-sec-0018}
----------------------------------------------------------------------------------------------------------------------------------

In the TME, cancer cells are affected by various cytokines produced by stromal cells. TGF‐β signals are well known inducers of the mesenchymal transition of OSCCs.[^31^](#cas14455-bib-0031){ref-type="ref"} We previously reported that TGF‐β and TNF‐α cooperate to induce EMT of lung cancer cells.[^24^](#cas14455-bib-0024){ref-type="ref"} Furthermore, activin signals have been shown to induce the EMT of OSCC lines.[^32^](#cas14455-bib-0032){ref-type="ref"} The OSCC line HSC‐4 was used in our study to examine whether cytokines, including TGF‐β2, activin, and TNF‐α, produced by mesenchymal cells originating from ECs could affect cancer cells. Treatment of HSC‐4 cells with TGF‐β1 increased expression of TMEPAI, a target of TGF‐β signals (Figure [S4](#cas14455-sup-0001){ref-type="supplementary-material"}A), vimentin (Figure [S4](#cas14455-sup-0001){ref-type="supplementary-material"}B,D), and fibronectin (Figure [S4](#cas14455-sup-0001){ref-type="supplementary-material"}C), markers of mesenchymal cells, and decreased E‐cadherin expression (Figure [S4](#cas14455-sup-0001){ref-type="supplementary-material"}D), suggesting that TGF‐β signals induced EMT of HSC‐4 cells. HUAECs were cultured in the presence of TGF‐β2, TNF‐α, or a combination of both cytokines for 60 h. HSC‐4 cells were then grown in HUAEC CM for 72 h, followed by qRT‐PCR analysis for expression of TMEPAI and various mesenchymal cell markers (Figure [9](#cas14455-fig-0009){ref-type="fig"}). Consistent with results using HEK‐Blue cells (Figure [8B](#cas14455-fig-0008){ref-type="fig"}), TMEPAI expression in HSC‐4 cells was induced by the CM derived from TGF‐β2‐treated HUAECs (Figure [9A](#cas14455-fig-0009){ref-type="fig"}). This effect was further increased by the CM obtained from TGF‐β2 and TNF‐α (Figure [9A](#cas14455-fig-0009){ref-type="fig"}). Furthermore, we found increased expression of vimentin (Figure [9B](#cas14455-fig-0009){ref-type="fig"}) and fibronectin (Figure [9C](#cas14455-fig-0009){ref-type="fig"}) when HSC‐4 cells were cultured in the CM derived from TGF‐β2‐treated HUAECs. Moreover, significantly increased levels of both transcripts were observed in HSC‐4 cells exposed to the CM obtained from TGF‐β2 and TNF‐α‐treated HUAECs (Figure [9B,C](#cas14455-fig-0009){ref-type="fig"}).

![Effects of HUAEC conditioned medium (CM) on the expression of TMEPAI and mesenchymal cell markers in HSC‐4 oral cancer cells. (A‐C) HUAECs were cultured in the absence (−) or presence (+) of 1 ng/mL TGF‐β2 in combination with 10 ng/mL TNF‐α for 60 h, followed by replacement with DMEM supplemented with 1% FBS and further culture for 16 h. HSC‐4 cells were cultured in the CM derived from HUAECs for 72 h, followed by qRT‐PCR analyses for expression of *TMEPAI* (A), vimentin (B), and fibronectin (C). (D‐F) HSC‐4 cells were cultured in the CM derived from HUAECs, in the absence (−) or presence (+) of 50 ng/mL follistatin, control IgG (50 μg/mL), and anti‐TGF‐β neutralizing antibody (1D11: 50 μg/mL) for 72 h, followed by qRT‐PCR analysis for expression of vimentin (D, E) and fluorescence immunostaining for E‐cadherin (green), vimentin (red) and nuclei (blue) (F). Error bars represent standard deviation. \**P* \<0.05; n.s., not significant. Scale bar, 25 μm](CAS-111-2385-g009){#cas14455-fig-0009}

To examine whether TGF‐β2 (Figure [5C](#cas14455-fig-0005){ref-type="fig"}) and activin A (Figure [5E](#cas14455-fig-0005){ref-type="fig"}) produced by HUAECs play a role in induction of EMT of HSC‐4 cells, we cultured HSC‐4 cells in the CM from HUAECs treated with TGF‐β2 and TNF‐α in combination with follistatin or anti‐TGF‐β neutralizing antibody, followed by qRT‐PCR analysis for expression of vimentin. We found that increased expression of vimentin by the CM derived from HUAECs treated with TGF‐β2 and TNF‐α was not affected by follistatin (Figure [9D](#cas14455-fig-0009){ref-type="fig"}) but it was significantly decreased by anti‐TGF‐β neutralizing antibody (Figure [9E](#cas14455-fig-0009){ref-type="fig"}). We also confirmed these results by performing immunocytochemical analyses for the expression of E‐cadherin and vimentin, epithelial and mesenchymal cell markers, respectively (Figure [9F](#cas14455-fig-0009){ref-type="fig"}). Together with the data of Smad2/3 activation (Figure [8](#cas14455-fig-0008){ref-type="fig"}), these results suggested that the CM derived from ECs, treated with exogenous TGF‐β2 and TNF‐α, stimulated secretion of active TGF‐β ligands by interaction with HSC‐4 cells. Our data also suggest that the TGF‐β ligands played a major role in the induction of the EMT of HSC‐4 cells compared with the secreted activin A.

4. DISCUSSION {#cas14455-sec-0019}
=============

In this study, we revealed that the EndMT was induced by TGF‐β2 and further enhanced by TNF‐α in various types of human ECs. While all of these stimulatory effects of TNF‐α on TGF‐β2‐induced EndMT were not observed in the mouse TECs isolated from human melanoma xenografts in nude mice (data not shown), the differential effects of TNF‐α might have been caused by the specific characteristics of mouse TECs which often have genomic instability[^33^](#cas14455-bib-0033){ref-type="ref"} and epigenetic alterations.[^34^](#cas14455-bib-0034){ref-type="ref"} Effects of TNF‐α on TGF‐β2‐induced EndMT in various types of ECs need to be studied more extensively in the future. Furthermore, we found that activation of the autocrine signal loop mediated by endogenous secretion of TGF‐β2 and activin A from ECs undergoing EndMT was likely to have caused the irreversible and long‐lasting effects induced by exogenous TGF‐β2 and TNF‐α, leading to the EMT of epithelial cancer cells.

We observed upregulated TMEPAI expression in HUAECs, even at 72 h post‐stimulation (Figure [1C](#cas14455-fig-0001){ref-type="fig"}), suggesting sustained activation of Smad2/3 signals. This effect was likely mediated by increased production of activin A in response to treatment with TGF‐β2 and TNF‐α (Figure [5](#cas14455-fig-0005){ref-type="fig"}), resulting in activation of an autocrine signaling loop. Furthermore, we found that TGF‐β2 and TNF‐α upregulated ALK5 (Figure [5](#cas14455-fig-0005){ref-type="fig"}A) and integrin αv (Figure [5](#cas14455-fig-0005){ref-type="fig"}F) expression, which can augment TGF‐β signals. Our data suggested that autocrine TGF‐β and activin signals are stabilized once Smad2/3 signals triggered by exogenous TGF‐β are activated.

Furthermore, we showed that TNF‐α could enhance the EndMT induced by TGF‐β likely to be through a direct effect on the TGF‐β signaling pathway. Liu and colleagues reported that ALK5 expression could be affected by inflammatory cytokines. In their study, treatment of lung carcinoma cells with a mixture of TNF‐α, IL‐1β, and interferon‐γ upregulated ALK5 expression.[^35^](#cas14455-bib-0035){ref-type="ref"} Consistent with their results, ALK5 expression in our study was primarily induced by TNF‐α, and the effect of TNF‐α was further enhanced by TGF‐β. TGF‐β could not enhance TNF‐α‐induced ICAM1 expression at 4 h post‐stimulation (Figure [1B](#cas14455-fig-0001){ref-type="fig"}), but suppressed it at 72 h post‐stimulation. During acute inflammation in the body, while TNF‐α functions as a proinflammatory cytokine in the onset phase, TGF‐β functions as an anti‐inflammatory cytokine in the resolution phase.[^36^](#cas14455-bib-0036){ref-type="ref"} For effective response in acute inflammation, TGF‐β signals need to be suppressed by TNF‐α at the onset phase and, in turn, the TNF‐α signal needs to be suppressed by TGF‐β at the resolution phase.[^37^](#cas14455-bib-0037){ref-type="ref"} ECs may thus have an internal system to regulate these signals for acute inflammation. Consistent with previous reports that have revealed crosstalk between TNF‐α and TGF‐β signaling pathways in a variety of cells,[^38^](#cas14455-bib-0038){ref-type="ref"}, [^39^](#cas14455-bib-0039){ref-type="ref"} the present study also highlighted the roles of RelA, a component of NF‐κB complex of TNF‐α signals in the regulation of TGF‐β‐induced expression of putative EndMT‐related molecules including SM22α as well as a TGF‐β target gene, *TMEPAI* (Figure [6](#cas14455-fig-0006){ref-type="fig"}C). This study suggested that cooperation between these cytokines in ECs occurred at the transcription level of each signaling molecule. Whether the expression of these genes is regulated by the crosstalk between Smad and NF‐κB signals needs to be elucidated in future studies.

In this study, we found that expression of TGF‐β2, but not TGF‐β1 or TGF‐β3, was upregulated by combined treatment with TGF‐β2 and TNF‐α (Figure [5](#cas14455-fig-0005){ref-type="fig"}). The expression of the human LDS4 gene encoding TGF‐β2 is known to be regulated by multiple promoter‐region‐specific AP‐1, AP‐2, SP‐1, and ATF‐2 transcription factor binding elements. The regulation also involves TATA box and cAMP‐responsive elements activated by ATF‐1.[^40^](#cas14455-bib-0040){ref-type="ref"}, [^41^](#cas14455-bib-0041){ref-type="ref"} In addition, induction of TGF‐β2 expression by TGF‐β1 or all‐*trans* retinoic acid involves direct activation of RhoA/ROCK signaling in multiple types of cells.[^42^](#cas14455-bib-0042){ref-type="ref"}, [^43^](#cas14455-bib-0043){ref-type="ref"}, [^44^](#cas14455-bib-0044){ref-type="ref"} Therefore, the precise mechanism underlying the regulation of TGF‐β2 expression in ECs remains to be elucidated.

Multiple lines of evidence have suggested that TGF‐β2 is overexpressed in various cancer types, including glioma, and that its expression is correlated with tumor progression.[^45^](#cas14455-bib-0045){ref-type="ref"} In addition, in human pancreatic cancer, all 3 isoforms of TGF‐β (TGF‐β1, 2, and 3) were expressed at higher levels compared with the normal pancreas.[^46^](#cas14455-bib-0046){ref-type="ref"} However, there was a correlation with advanced tumor stage and a more aggressive metastasizing tumor phenotype when the TGF‐β2 isoform was overexpressed in tumor tissue or plasma, as proven both by animal studies and some clinical observations in humans.[^46^](#cas14455-bib-0046){ref-type="ref"}, [^47^](#cas14455-bib-0047){ref-type="ref"} In our study, we found that ECs, representing an important constituent of the TME, became the source of TGF‐β2 and activin (Figure [5](#cas14455-fig-0005){ref-type="fig"}). Cancer stem cells (CSCs) are tumor cells that have the characteristics of self‐renewal ability, tumor initiation capacity, and drug resistance.[^48^](#cas14455-bib-0048){ref-type="ref"} CSCs reside in niches, which are distinct regions within the TME, preserving the properties of CSCs at least partially by the cytokines secreted by the niche components. Multiple lines of evidence have suggested that ECs in the TME establish a "vascular niche" by secreting various cytokines.[^49^](#cas14455-bib-0049){ref-type="ref"} Taken together with the notion that EMT activation is linked to the acquisition of stem cell properties of cancer cells,[^50^](#cas14455-bib-0050){ref-type="ref"} TGF‐β2 secreted by ECs undergoing EndMT is likely to mediate the crosstalk between tumor and stromal cells, promoting tumor progression via induction of the EMT of cancer cells.

While anti‐TGF‐β neutralizing antibody (1D11) abrogated the induction of EMT of HSC‐4 oral cancer cells by the CM from HUAECs treated with TGF‐β2 and TNF‐α (Figure [9E,F](#cas14455-fig-0009){ref-type="fig"}), activation of Smad2/3 signals by the CM was not inhibited in the presence of the antibody (Figure [8D](#cas14455-fig-0008){ref-type="fig"}). TGF‐β is produced as a latent form, which can be activated in vitro and in vivo only under certain conditions. Sato and colleagues reported that latent TGF‐β was activated in co‐culture of ECs and smooth muscle cells.[^51^](#cas14455-bib-0051){ref-type="ref"} As anti‐TGF‐β neutralizing antibody targets activated TGF‐βs, it may have failed to deplete TGF‐βs from the CM of HUAECs and thus we observed activation of Smad2/3 signals in HEK‐Blue reporter cells (Figure [8D](#cas14455-fig-0008){ref-type="fig"}). The present finding that the antibody suppressed the CM to induce the EMT of HSC‐4 oral cancer cells (Figure [9E,F](#cas14455-fig-0009){ref-type="fig"}) suggested that latent TGF‐βs in the CM may be activated via interaction with multiple components of HSC‐4 cells. As ECs and cancer cells interact with each other in TME, it is crucial to understand the mechanisms of how endothelial cell‐derived latent TGF‐βs are activated by cancer cells to establish novel therapeutic strategies targeting the TME.

Several attempts to inhibit TGF‐β2 in tumor tissues have been reported. TGF‐β2 antisense compound has been clinically evaluated in patients with high‐grade glioma, pancreatic and colorectal cancers, and melanoma, resulting in the reversal of tumor‐induced immune suppression and inhibition of tumor growth, invasion, and metastasis.[^52^](#cas14455-bib-0052){ref-type="ref"}, [^53^](#cas14455-bib-0053){ref-type="ref"}, [^54^](#cas14455-bib-0054){ref-type="ref"} The present study identified multiple target molecules, including activin and integrin αv, which showed increased expression in ECs undergoing EndMT. Importantly, it also raised the possibility that the inhibition of TGF‐β signals is significantly effective to suppress the EndMT‐driven EMT. The efficacy of the targeting strategies needs to be studied in vivo using tumor models in which EndMT plays important roles in tumor progression. Furthermore, as the EndMT has been implicated in other types of human diseases, including organ fibrosis,[^55^](#cas14455-bib-0055){ref-type="ref"}, [^56^](#cas14455-bib-0056){ref-type="ref"}, [^57^](#cas14455-bib-0057){ref-type="ref"} atherosclerosis,[^58^](#cas14455-bib-0058){ref-type="ref"} pulmonary arterial hypertension,[^59^](#cas14455-bib-0059){ref-type="ref"} and cerebral cavernous malformation,[^10^](#cas14455-bib-0010){ref-type="ref"} these molecules are expected to be good targets for prevention and treatment of pathological conditions caused by EndMT.
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